New Delhi: Disposing of cases of faulty hip implants sold by a pharma major, the Supreme Court on Friday accepted the submissions of the Centre to grant to the victims compensation ranging between Rs 3 lakh and Rs 1.22 crore. The apex court asked the Centre to give proper publicity to the scheme. Also Read - India to be Renamed 'Bharat'? Twitter Uses Harpic as Eyedrop to Undo Watching News, Asks Supreme Court to Sort Priorities Amid COVID-19 And Migrant Crisis

The Government had filed an affidavit in the SC urging it to direct US-based pharmaceutical giant Johnson and Johnson Pvt. Ltd to compensate patients as per the formula approved by the Union Health Ministry. According to the formula, Indian patients suffering because of the hip implants sold by the company would get as much as Rs 1.2 crore each and an additional Rs 10 lakh for non-pecuniary losses. The minimum compensation according to the formula in case of a disability would be Rs 33 lakh. Also Read - 'Close Your Legs': Judge's Advice to Woman, For Prevention of Sexual Assault, Costs Him His Job

The health ministry had said on November 29, 2018, said that patients could “secure compensation from Johnson and Johnson in days to come”. “Compensation will be paid in a time-bound manner through bank accounts of affected persons by Johnson and Johnson Pvt. Ltd,” the health ministry had said. Apparently, the government was waiting for the acceptance from the company following a letter which was written to it on November 30 last year. But company challenged the government’s formula, blaming the government for lack of transparency while devising the formula. Also Read - States Should Not Charge Travel Fare From Migrants And Need to Provide Food, Water to Them, Says Supreme Court

Meanwhile, the government also started a fresh round of discussions on the formula. Both- company and the group of patients shared their grievances with the expert committee on 9 January.

As many as 4,700 Articular Surface Replacement (ASR) surgeries were carried out in India between 2004 and 2010. However, only 1,080 patients could be traced through the ASR helpline. ASR was sold in India by DePuy International, a subsidiary of the pharmaceutical giant.